Venus Remedies receives European patent for VRP008

Venus Remedies has received another patent grant for a novel antibiotic product VRP008 consisting of a carbapenem and a novel aminoglycoside (NCE entity) from European Patent Office (EPO). Pioneering into antimicrobial resistance research, VMRC is engaged in research for this product from the past 8 years. The product is designed for mixed multi-drug infections for pediatric, geriatric and adult immuno-compromised patients where the risk of adverse events is high and very low amount of doses are required. It is expected to capture a wide range of market sector which is upheaval with antibiotics for wide indications.  Besides this, Venus has also received EU patent for its novel product Elores, Potentox, Vancoplus and Achnil. Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.